Adage Capital Partners’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-8,925,010
| Closed | -$355M | – | 1015 |
|
|
2026
Q1 | $355M | Sell |
8,925,010
-2,356,731
| -21% | -$60.3M | 0.55% | 25 |
|
|
2025
Q4 | $282M | Buy |
11,281,741
+1,246,741
| +12% | +$31.6M | 0.43% | 37 |
|
|
2025
Q3 | $243M | Buy |
10,035,000
+1,632,000
| +19% | +$29M | 0.39% | 37 |
|
|
2025
Q2 | $110M | Buy |
8,403,000
+1,449,000
| +21% | +$18.4M | 0.19% | 105 |
|
|
2025
Q1 | $100M | Buy |
6,954,000
+1,834,973
| +36% | +$30M | 0.19% | 112 |
|
|
2024
Q4 | $85.7M | Buy |
5,119,027
+924,027
| +22% | +$15.3M | 0.15% | 127 |
|
|
2024
Q3 | $67.1M | Buy |
4,195,000
+1,070,000
| +34% | +$13.1M | 0.12% | 184 |
|
|
2024
Q2 | $28.2M | Buy |
3,125,000
+875,000
| +39% | +$8.3M | 0.05% | 355 |
|
|
2024
Q1 | $25.4M | Sell |
2,250,000
-646,128
| -22% | -$6.12M | 0.05% | 388 |
|
|
2023
Q4 | $23.1M | Buy |
2,896,128
+65,628
| +2% | +$440K | 0.05% | 386 |
|
|
2023
Q3 | $18.3M | Buy |
2,830,500
+580,500
| +26% | +$3.97M | 0.04% | 417 |
|
|
2023
Q2 | $13.9M | Buy |
+2,250,000
| New | +$10.7M | 0.03% | 499 |
|
Adage Capital Partners's CNTA Position: Q2 2026 in Review
Adage Capital Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 8,925,010 shares — an estimated $355M sold.
Adage Capital Partners first reported a position in CNTA in Q2 2023 and held it in 12 quarters. The position peaked at $355M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Adage Capital Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Adage Capital Partners sold 8,925,010 Centessa Pharmaceuticals shares in Q2 2026, an estimated $355M.
- Adage Capital Partners first reported a position in Centessa Pharmaceuticals in Q2 2023 and held it in 12 quarters.
- Adage Capital Partners's Centessa Pharmaceuticals position peaked at $355M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.